Evidence map›Paper›PMID 32393489›Full record

ArticleAntimicrobial agents and chemotherapy2020

Antileishmanial Effects of Synthetic

Helena Fehling, Siew Ling Choy, Frederic Ting, Dirk Landschulze, Hannah Bernin, Sarah Corinna Lender, Melina Mühlenpfordt, Eugenia Bifeld, Julia Eick, Claudia Marggraff and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Helena Fehling *Department of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Siew Ling Choy *Department of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Frederic Ting *Department of Chemistry, University of Hamburg, Hamburg, Germany.
Dirk LandschulzeDepartment of Chemistry, University of Hamburg, Hamburg, Germany.
Hannah BerninDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Sarah Corinna LenderDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Melina MühlenpfordtDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Eugenia BifeldLeishmaniasis Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Julia EickLeishmaniasis Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Claudia MarggraffDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Nadine KottmayrDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Marie GronebergDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Stefan HoenowDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Julie SellauDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Joachim ClosLeishmaniasis Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.ORCID 0000-0003-4377-8173
Chris MeierDepartment of Chemistry, University of Hamburg, Hamburg, Germany.
Hannelore LotterDepartment of Molecular Parasitology and Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany lotter@bnitm.de.
Bernhard Nocht Institute for Tropical Medicine · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid molecule of the intestinal protozoan parasite

Indexed as

Antiprotozoal AgentsEntamoeba histolyticaLeishmania majorLeishmaniasis, CutaneousPharmaceutical PreparationsAnimalsHumansMiceMice, Inbred BALB CAntiprotozoal AgentsPharmaceutical PreparationsimmunostimulationLeishmania

Identifiers

PMID32393489
PMCPMC7318009
OpenAlexW3022909942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.